NBW Capital LLC Sells 1,791 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

NBW Capital LLC decreased its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 3.4% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 50,944 shares of the biotechnology company’s stock after selling 1,791 shares during the quarter. NBW Capital LLC owned 0.08% of Blueprint Medicines worth $4,833,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of the business. Covestor Ltd increased its holdings in Blueprint Medicines by 9,700.0% in the 1st quarter. Covestor Ltd now owns 294 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 291 shares in the last quarter. Headlands Technologies LLC raised its position in shares of Blueprint Medicines by 105.2% during the 1st quarter. Headlands Technologies LLC now owns 667 shares of the biotechnology company’s stock valued at $63,000 after purchasing an additional 342 shares during the period. Natixis purchased a new position in shares of Blueprint Medicines during the 1st quarter valued at $73,000. Van ECK Associates Corp lifted its stake in shares of Blueprint Medicines by 28.4% during the 4th quarter. Van ECK Associates Corp now owns 872 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 193 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new position in Blueprint Medicines in the 4th quarter worth $95,000.

Blueprint Medicines Trading Down 3.6 %

BPMC traded down $3.57 during trading on Friday, hitting $96.72. 1,779,789 shares of the stock were exchanged, compared to its average volume of 758,420. Blueprint Medicines Co. has a 1 year low of $43.89 and a 1 year high of $121.90. The firm has a market cap of $6.06 billion, a price-to-earnings ratio of -20.11 and a beta of 0.63. The firm has a 50 day simple moving average of $108.75 and a 200 day simple moving average of $97.20. The company has a debt-to-equity ratio of 0.67, a quick ratio of 3.61 and a current ratio of 3.76.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($1.29) by $0.49. Blueprint Medicines had a negative return on equity of 176.65% and a negative net margin of 56.64%. The firm had revenue of $138.20 million for the quarter, compared to analyst estimates of $104.02 million. During the same quarter last year, the firm posted ($2.19) earnings per share. The business’s revenue for the quarter was up 139.9% on a year-over-year basis. As a group, equities analysts expect that Blueprint Medicines Co. will post -4.67 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on BPMC shares. Needham & Company LLC restated a “buy” rating and issued a $130.00 price objective on shares of Blueprint Medicines in a research report on Thursday. Guggenheim lifted their price objective on shares of Blueprint Medicines from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Friday. Wedbush restated an “outperform” rating and set a $110.00 target price on shares of Blueprint Medicines in a research report on Friday, April 26th. JMP Securities reaffirmed a “market outperform” rating and set a $125.00 target price on shares of Blueprint Medicines in a research note on Friday, June 7th. Finally, Stephens assumed coverage on shares of Blueprint Medicines in a research note on Tuesday, May 14th. They issued an “overweight” rating and a $140.00 price target on the stock. One research analyst has rated the stock with a sell rating, six have given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $120.00.

Insider Transactions at Blueprint Medicines

In related news, insider Debra Durso-Bumpus sold 74,034 shares of the business’s stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $104.19, for a total value of $7,713,602.46. Following the completion of the transaction, the insider now owns 43,763 shares of the company’s stock, valued at $4,559,666.97. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Blueprint Medicines news, insider Debra Durso-Bumpus sold 74,034 shares of the business’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $104.19, for a total value of $7,713,602.46. Following the completion of the transaction, the insider now directly owns 43,763 shares in the company, valued at $4,559,666.97. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Percy H. Carter sold 4,000 shares of Blueprint Medicines stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $105.13, for a total transaction of $420,520.00. Following the completion of the transaction, the insider now directly owns 41,895 shares in the company, valued at approximately $4,404,421.35. The disclosure for this sale can be found here. In the last quarter, insiders sold 130,064 shares of company stock valued at $13,716,726. Company insiders own 4.21% of the company’s stock.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.